nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Phentermine—obesity	0.181	0.305	CbGbCtD
Methylnaltrexone—CYP2D6—Bupropion—obesity	0.154	0.26	CbGbCtD
Methylnaltrexone—CYP2D6—Methamphetamine—obesity	0.144	0.244	CbGbCtD
Methylnaltrexone—CYP2D6—Cimetidine—obesity	0.113	0.191	CbGbCtD
Methylnaltrexone—Hyperhidrosis—Benzphetamine—obesity	0.00463	0.0277	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methamphetamine—obesity	0.00428	0.0257	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Phendimetrazine—obesity	0.00422	0.0253	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Benzphetamine—obesity	0.00413	0.0248	CcSEcCtD
Methylnaltrexone—Naloxone—TLR4—obesity	0.00394	0.711	CrCbGaD
Methylnaltrexone—Erythema—Diethylpropion—obesity	0.0038	0.0228	CcSEcCtD
Methylnaltrexone—Redness—Topiramate—obesity	0.00364	0.0218	CcSEcCtD
Methylnaltrexone—Oedema—Phentermine—obesity	0.00357	0.0214	CcSEcCtD
Methylnaltrexone—Flatulence—Cimetidine—obesity	0.00356	0.0214	CcSEcCtD
Methylnaltrexone—Abdominal pain—Phendimetrazine—obesity	0.00345	0.0207	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methamphetamine—obesity	0.0034	0.0204	CcSEcCtD
Methylnaltrexone—Dizziness—Methamphetamine—obesity	0.00328	0.0197	CcSEcCtD
Methylnaltrexone—Diarrhoea—Benzphetamine—obesity	0.00327	0.0196	CcSEcCtD
Methylnaltrexone—Dizziness—Benzphetamine—obesity	0.00316	0.019	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Phentermine—obesity	0.00308	0.0185	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Diethylpropion—obesity	0.003	0.018	CcSEcCtD
Methylnaltrexone—Diarrhoea—Phendimetrazine—obesity	0.00298	0.0179	CcSEcCtD
Methylnaltrexone—Dizziness—Phendimetrazine—obesity	0.00288	0.0173	CcSEcCtD
Methylnaltrexone—Nausea—Benzphetamine—obesity	0.00284	0.017	CcSEcCtD
Methylnaltrexone—Abdominal pain—Phentermine—obesity	0.00282	0.0169	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Diethylpropion—obesity	0.00268	0.0161	CcSEcCtD
Methylnaltrexone—Nausea—Phendimetrazine—obesity	0.00259	0.0155	CcSEcCtD
Methylnaltrexone—Dizziness—Phenylpropanolamine—obesity	0.00246	0.0148	CcSEcCtD
Methylnaltrexone—Diarrhoea—Phentermine—obesity	0.00244	0.0146	CcSEcCtD
Methylnaltrexone—Vomiting—Phenylpropanolamine—obesity	0.00237	0.0142	CcSEcCtD
Methylnaltrexone—Dizziness—Phentermine—obesity	0.00236	0.0141	CcSEcCtD
Methylnaltrexone—Vomiting—Phentermine—obesity	0.00227	0.0136	CcSEcCtD
Methylnaltrexone—Nausea—Phenylpropanolamine—obesity	0.00221	0.0133	CcSEcCtD
Methylnaltrexone—Diarrhoea—Diethylpropion—obesity	0.00212	0.0127	CcSEcCtD
Methylnaltrexone—Nausea—Phentermine—obesity	0.00212	0.0127	CcSEcCtD
Methylnaltrexone—Dizziness—Diethylpropion—obesity	0.00205	0.0123	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cimetidine—obesity	0.00202	0.0121	CcSEcCtD
Methylnaltrexone—Vomiting—Diethylpropion—obesity	0.00197	0.0118	CcSEcCtD
Methylnaltrexone—Flatulence—Orlistat—obesity	0.00197	0.0118	CcSEcCtD
Methylnaltrexone—Dizziness—Cimetidine—obesity	0.00195	0.0117	CcSEcCtD
Methylnaltrexone—Flatulence—Sibutramine—obesity	0.0019	0.0114	CcSEcCtD
Methylnaltrexone—Vomiting—Cimetidine—obesity	0.00188	0.0112	CcSEcCtD
Methylnaltrexone—Nausea—Diethylpropion—obesity	0.00184	0.011	CcSEcCtD
Methylnaltrexone—Nausea—Cimetidine—obesity	0.00175	0.0105	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.00169	0.0101	CcSEcCtD
Methylnaltrexone—Flatulence—Bupropion—obesity	0.00166	0.00995	CcSEcCtD
Methylnaltrexone—Oedema—Orlistat—obesity	0.00163	0.00977	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Orlistat—obesity	0.0016	0.00958	CcSEcCtD
Methylnaltrexone—Skin disorder—Orlistat—obesity	0.00158	0.00949	CcSEcCtD
Methylnaltrexone—Oedema—Sibutramine—obesity	0.00158	0.00945	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Orlistat—obesity	0.00157	0.00944	CcSEcCtD
Methylnaltrexone—Skin disorder—Sibutramine—obesity	0.00153	0.00918	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Sibutramine—obesity	0.00152	0.00914	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.00142	0.00854	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Orlistat—obesity	0.00141	0.00843	CcSEcCtD
Methylnaltrexone—Pain—Orlistat—obesity	0.00139	0.00835	CcSEcCtD
Methylnaltrexone—Oedema—Bupropion—obesity	0.00137	0.00824	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Sibutramine—obesity	0.00136	0.00816	CcSEcCtD
Methylnaltrexone—Pain—Sibutramine—obesity	0.00135	0.00808	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Bupropion—obesity	0.00135	0.00808	CcSEcCtD
Methylnaltrexone—Skin disorder—Bupropion—obesity	0.00134	0.00801	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Orlistat—obesity	0.00133	0.00799	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Bupropion—obesity	0.00133	0.00797	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Sibutramine—obesity	0.00129	0.00773	CcSEcCtD
Methylnaltrexone—Abdominal pain—Orlistat—obesity	0.00129	0.00772	CcSEcCtD
Methylnaltrexone—Abdominal pain—Sibutramine—obesity	0.00125	0.00747	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Bupropion—obesity	0.00119	0.00712	CcSEcCtD
Methylnaltrexone—Pain—Bupropion—obesity	0.00118	0.00705	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Bupropion—obesity	0.00112	0.00674	CcSEcCtD
Methylnaltrexone—Diarrhoea—Orlistat—obesity	0.00111	0.00668	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—obesity	0.0011	0.2	CrCbGaD
Methylnaltrexone—Abdominal pain—Bupropion—obesity	0.00109	0.00651	CcSEcCtD
Methylnaltrexone—Diarrhoea—Sibutramine—obesity	0.00108	0.00647	CcSEcCtD
Methylnaltrexone—Dizziness—Orlistat—obesity	0.00108	0.00646	CcSEcCtD
Methylnaltrexone—Erythema—Topiramate—obesity	0.00107	0.00643	CcSEcCtD
Methylnaltrexone—Flatulence—Topiramate—obesity	0.00106	0.00634	CcSEcCtD
Methylnaltrexone—Dizziness—Sibutramine—obesity	0.00104	0.00625	CcSEcCtD
Methylnaltrexone—Vomiting—Orlistat—obesity	0.00104	0.00621	CcSEcCtD
Methylnaltrexone—Vomiting—Sibutramine—obesity	0.001	0.00601	CcSEcCtD
Methylnaltrexone—Nausea—Orlistat—obesity	0.000968	0.0058	CcSEcCtD
Methylnaltrexone—Diarrhoea—Bupropion—obesity	0.00094	0.00564	CcSEcCtD
Methylnaltrexone—Nausea—Sibutramine—obesity	0.000937	0.00562	CcSEcCtD
Methylnaltrexone—Dizziness—Bupropion—obesity	0.000909	0.00545	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000907	0.00544	CcSEcCtD
Methylnaltrexone—Oedema—Topiramate—obesity	0.000876	0.00525	CcSEcCtD
Methylnaltrexone—Vomiting—Bupropion—obesity	0.000874	0.00524	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Topiramate—obesity	0.000859	0.00515	CcSEcCtD
Methylnaltrexone—Skin disorder—Topiramate—obesity	0.000851	0.0051	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Topiramate—obesity	0.000847	0.00508	CcSEcCtD
Methylnaltrexone—Nausea—Bupropion—obesity	0.000816	0.0049	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Topiramate—obesity	0.000756	0.00453	CcSEcCtD
Methylnaltrexone—Pain—Topiramate—obesity	0.000749	0.00449	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Topiramate—obesity	0.000716	0.00429	CcSEcCtD
Methylnaltrexone—Abdominal pain—Topiramate—obesity	0.000692	0.00415	CcSEcCtD
Methylnaltrexone—Diarrhoea—Topiramate—obesity	0.000599	0.00359	CcSEcCtD
Methylnaltrexone—Dizziness—Topiramate—obesity	0.000579	0.00347	CcSEcCtD
Methylnaltrexone—Vomiting—Topiramate—obesity	0.000557	0.00334	CcSEcCtD
Methylnaltrexone—Nausea—Topiramate—obesity	0.00052	0.00312	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—obesity	0.000491	0.0888	CrCbGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT2—obesity	5.41e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—HTR2A—obesity	5.41e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—C3—obesity	5.4e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—DRD2—obesity	5.4e-05	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—obesity	5.37e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PNLIP—obesity	5.35e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SRD5A1—obesity	5.35e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GCG—obesity	5.34e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTPN1—obesity	5.34e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NPS—obesity	5.31e-05	0.000225	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PRKCB—obesity	5.22e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—F2—obesity	5.22e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDC3—obesity	5.22e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD1—obesity	5.21e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2C—obesity	5.21e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—obesity	5.2e-05	0.00022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGT—obesity	5.13e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—obesity	5.11e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP26B1—obesity	5.1e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STS—obesity	5.1e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HK2—obesity	5.1e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRL—obesity	5.1e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NTRK2—obesity	5.07e-05	0.000214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB1—obesity	5.04e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STK11—obesity	5.02e-05	0.000212	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—obesity	5e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—obesity	5e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARD—obesity	4.99e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLG—obesity	4.97e-05	0.00021	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—RHOA—obesity	4.96e-05	0.00021	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PARP1—obesity	4.94e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—obesity	4.94e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT2—obesity	4.91e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3R1—obesity	4.91e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD4—obesity	4.9e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC27A1—obesity	4.89e-05	0.000207	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FOXO3—obesity	4.85e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB2—obesity	4.84e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FABP4—obesity	4.79e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GLUL—obesity	4.79e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS1—obesity	4.76e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—obesity	4.76e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—F2—obesity	4.74e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCB—obesity	4.74e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—obesity	4.72e-05	0.0002	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SOCS3—obesity	4.7e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR1—obesity	4.68e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNB3—obesity	4.61e-05	0.000195	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TCF7L2—obesity	4.59e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT2—obesity	4.57e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—DRD2—obesity	4.56e-05	0.000193	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD11B1—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UCP2—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UCP3—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ECHS1—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—TYK2—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—obesity	4.54e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—obesity	4.53e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF2—obesity	4.52e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GCG—obesity	4.52e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTPN1—obesity	4.52e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RHOA—obesity	4.5e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNAS—obesity	4.48e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADH1B—obesity	4.47e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3R1—obesity	4.46e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACSL1—obesity	4.4e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARGC1B—obesity	4.4e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPAM—obesity	4.4e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—obesity	4.39e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOB—obesity	4.39e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—obesity	4.32e-05	0.000183	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRL—obesity	4.31e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL5—obesity	4.29e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PCK1—obesity	4.27e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HADH—obesity	4.27e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FADS1—obesity	4.27e-05	0.000181	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STK11—obesity	4.25e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—obesity	4.23e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLG—obesity	4.2e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LPL—obesity	4.19e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—RHOA—obesity	4.19e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FOXO1—obesity	4.16e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACP5—obesity	4.16e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RPS6KB1—obesity	4.16e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT2—obesity	4.15e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3R1—obesity	4.15e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—obesity	4.11e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FOXO3—obesity	4.1e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB2—obesity	4.09e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—G6PD—obesity	4.05e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS1—obesity	4.03e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SREBF2—obesity	4e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HK1—obesity	4e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—obesity	3.99e-05	0.000169	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SOCS3—obesity	3.98e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNB3—obesity	3.89e-05	0.000165	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPA—obesity	3.86e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCD—obesity	3.86e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—TYK2—obesity	3.84e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—obesity	3.83e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF2—obesity	3.82e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RHOA—obesity	3.81e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNAS—obesity	3.79e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPIN1—obesity	3.78e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2A—obesity	3.78e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—C3—obesity	3.78e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3R1—obesity	3.77e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOB—obesity	3.71e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA5—obesity	3.71e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL5—obesity	3.62e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS2—obesity	3.59e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGT—obesity	3.59e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LPL—obesity	3.54e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC22A1—obesity	3.53e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CLOCK—obesity	3.53e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FOXO1—obesity	3.52e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—obesity	3.51e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—obesity	3.51e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RPS6KB1—obesity	3.51e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CAV1—obesity	3.48e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—obesity	3.48e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA1—obesity	3.47e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT2A1—obesity	3.44e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GLP1R—obesity	3.44e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DPYD—obesity	3.39e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—obesity	3.36e-05	0.000142	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCB—obesity	3.31e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—F2—obesity	3.31e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BAD—obesity	3.28e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCD—obesity	3.26e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PRKAR2B—obesity	3.26e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—DCN—obesity	3.24e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2A—obesity	3.2e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—C3—obesity	3.19e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—obesity	3.17e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CPT1A—obesity	3.15e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS1—obesity	3.14e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAMPT—obesity	3.09e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCK—obesity	3.07e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LIPC—obesity	3.07e-05	0.00013	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOC3—obesity	3.05e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS2—obesity	3.04e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGT—obesity	3.03e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—obesity	3.02e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—obesity	3e-05	0.000127	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—obesity	2.97e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—obesity	2.97e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CETP—obesity	2.96e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—obesity	2.95e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CAV1—obesity	2.94e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA1—obesity	2.94e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SDC1—obesity	2.93e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—obesity	2.9e-05	0.000123	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT2—obesity	2.9e-05	0.000123	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C3—obesity	2.88e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SCARB1—obesity	2.84e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—obesity	2.84e-05	0.00012	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—F2—obesity	2.8e-05	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCB—obesity	2.8e-05	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—obesity	2.79e-05	0.000118	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BAD—obesity	2.77e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—obesity	2.76e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—obesity	2.76e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SREBF1—obesity	2.75e-05	0.000116	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TYK2—obesity	2.68e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—obesity	2.68e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT2—obesity	2.68e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RHOA—obesity	2.66e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS1—obesity	2.65e-05	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—obesity	2.63e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3R1—obesity	2.63e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—FASN—obesity	2.62e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCHE—obesity	2.61e-05	0.00011	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—obesity	2.55e-05	0.000108	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—obesity	2.54e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—obesity	2.52e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—obesity	2.51e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—obesity	2.5e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—obesity	2.49e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—obesity	2.45e-05	0.000104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT2—obesity	2.45e-05	0.000104	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—obesity	2.43e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTOR—obesity	2.43e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCG—obesity	2.39e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A4—obesity	2.39e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—obesity	2.36e-05	9.97e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYCS—obesity	2.36e-05	9.96e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—obesity	2.33e-05	9.87e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—obesity	2.33e-05	9.86e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GGT1—obesity	2.31e-05	9.78e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GOT1—obesity	2.31e-05	9.78e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA1—obesity	2.28e-05	9.63e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TYK2—obesity	2.27e-05	9.59e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—obesity	2.26e-05	9.54e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RHOA—obesity	2.25e-05	9.51e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STK11—obesity	2.24e-05	9.49e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP19A1—obesity	2.24e-05	9.49e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—obesity	2.23e-05	9.41e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3R1—obesity	2.23e-05	9.41e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—obesity	2.22e-05	9.39e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—obesity	2.12e-05	8.96e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—obesity	2.11e-05	8.93e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COMT—obesity	2.09e-05	8.83e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARGC1A—obesity	2.06e-05	8.7e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNB3—obesity	2.06e-05	8.7e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK8—obesity	2.05e-05	8.69e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTOR—obesity	2.05e-05	8.69e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—obesity	2.05e-05	8.69e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—obesity	2.05e-05	8.66e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—obesity	2.05e-05	8.66e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNAS—obesity	2e-05	8.47e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOB—obesity	1.96e-05	8.3e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—obesity	1.91e-05	8.06e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—obesity	1.88e-05	7.94e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—obesity	1.88e-05	7.94e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPL—obesity	1.87e-05	7.92e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—obesity	1.83e-05	7.73e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—obesity	1.79e-05	7.55e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD36—obesity	1.78e-05	7.53e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—obesity	1.75e-05	7.38e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—obesity	1.74e-05	7.36e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK8—obesity	1.74e-05	7.34e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—obesity	1.73e-05	7.32e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—obesity	1.69e-05	7.13e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARA—obesity	1.65e-05	7e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGT—obesity	1.6e-05	6.78e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—obesity	1.59e-05	6.71e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—obesity	1.57e-05	6.64e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAV1—obesity	1.56e-05	6.58e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA1—obesity	1.55e-05	6.56e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—obesity	1.48e-05	6.27e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—obesity	1.48e-05	6.24e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—obesity	1.47e-05	6.22e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—obesity	1.42e-05	5.99e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—obesity	1.37e-05	5.78e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—obesity	1.35e-05	5.7e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—obesity	1.34e-05	5.67e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—obesity	1.31e-05	5.55e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—obesity	1.25e-05	5.3e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—obesity	1.25e-05	5.27e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—obesity	1.23e-05	5.2e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—obesity	1.21e-05	5.12e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—obesity	1.18e-05	4.98e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3R1—obesity	1.18e-05	4.98e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—obesity	1.11e-05	4.69e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—obesity	1.09e-05	4.59e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—obesity	1.08e-05	4.55e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—obesity	1.02e-05	4.33e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—obesity	6.62e-06	2.8e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—obesity	5.41e-06	2.29e-05	CbGpPWpGaD
